Enanta Pharmaceuticals has initiated legal action against Pfizer (PFE) over a patent infringement related to Paxlovid, ...

With strong hedge fund interest and a low price-to-earnings ratio, Pfizer Inc. (NYSE:PFE) secures a place on our list of the ...

Pfizer (PFE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Pfizer beats Q2 estimates with $14.7B revenue and $0.78 EPS. Management showed extreme confidence by raising full-year EPS ...

Pfizer ($PFE) may finally be turning the corner on its post-pandemic revenue challenges. The company recently reported ...

In terms of liquidity and interest, the mean open interest for Pfizer options trades today is 13596.29 with a total volume of 13,024.00. In the following chart, we are able to follow the development ...

Pfizer (PFE) stock slips as a Phase 3 trial failure for its sickle cell disease therapy inclacumab marks the latest setback ...

Parnassus Investments, an investment management firm that focuses on owning a concentrated portfolio of U.S. large cap stocks ...

Pfizer Inc. (NYSE:PFE) discovers, develops, markets, and sells biopharmaceutical products in the U.S. and internationally. It ...

The final trades of the day with CNBC’s Melissa Lee and the "Fast Money" traders. ‘See You in Court’: Fox News Suffers Another Legal Blow ...

Pfizer Inc. (NYSE:PFE)’s shares jumped by 1.8% earlier this week after the firm announced that its bladder cancer drug Padcev helped improve bladder cancer survival rates when combined with ...